Monitor the poster presentation on July 12 for any data readouts on immune response or viral neutralization. No immediate trading catalyst; the stock may see limited movement unless the data reveals a clear differentiation from existing CMV vaccine approaches.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 1 $3.20entry
- T+1 · 5mo ago +6.56%α +6.69% · $3.41
- T+5 · 4mo ago +3.44%α +3.18% · $3.31
- T+20 · 4mo ago −11.25%α −9.06% · $2.84
- T+60 · 8w ago +1.88%α −1.08% · $3.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced a poster presentation of preclinical data for its CMV vaccine candidate EVX-V1 at the International Herpesvirus Workshop on July 12, 2026. The data will guide final antigen selection for the candidate, which combines AI-discovered and AI-optimized antigens. This is a routine pipeline update with no financial or clinical data disclosed.
Key Facts
- Evaxion will present preclinical data for CMV vaccine candidate EVX-V1 at IHW 2026 in Montreal on July 12, 2026.
- EVX-V1 is a multi-component vaccine combining novel AI-discovered antigens with AI-optimized versions of established CMV antigens.
- No CMV vaccine has been approved to date; the CMV treatment market was valued at $474.6M in 2023 with 6.6% CAGR forecast.
- The presentation will guide final antigen selection for a broadly protective CMV vaccine candidate.
Financial Impact
No financial figures disclosed; preclinical data presentation has no direct revenue or earnings impact.
Risk Factors
- Preclinical data may not translate to clinical efficacy or regulatory success.
- Evaxion is a clinical-stage company with no approved products and likely needs additional capital to fund development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004414 |
| Document: f6k_070126.htm | 0001171843-26-004414 |
| Document: 0001171843-26-004414-index-headers.html | 0001171843-26-004414 |
| Document: 0001171843-26-004414-index.html | 0001171843-26-004414 |
| Document: 0001171843-26-004414.txt | 0001171843-26-004414 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers